Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Epilepsy (Eslicarbazepine acetate - Epilepsy)

Records returned : 38 (on 04 Aug 2026 at 03:28:07). Return to search results for ' Epilepsy '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Indication :
Status :
Amber
Formulations :
  • Tablets
Restrictions / Comments:

Important

Only when 1st-line and 1st-line adjunctive agents have been unsuccessful

Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

 
Links :
R
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.

To be initiated by a specialist.

 
Links :
R
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important
Reserved for patients who remain uncontrolled or intolerant to all other adjuntive anti-epileptics. Only for use when levetiracetam has not been effective or tolerated.
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Modified release tablets
  • Oral suspension
  • Suppositories
  • Tablets
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important

For ADULTS, blue with specialist prescriber initation and supply for at least 12 weeks

 
Links :
Indication :
Status :
Non Formulary
Formulations :
  • Tablets
Restrictions / Comments:

Important

Non-formulary for CHILDREN.

Licensed for use in adults only

 
Links :
Off Label
SPC
Indication :
Status :
Blue
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
CD
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
CD
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral solution
Restrictions / Comments:

Important
For absence, atypical and myoclonic seizures
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
CD
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Infusion
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Dispersible tablets
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Granules
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Infusion
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Requires specialist initiation and supply for at least 12 weeks prior to a transfer of care to primary care prescribers
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Elixir
  • Tablets
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product
 
Links :
CD
SPC
Indication :
Status :
Blue
Formulations :
  • Liquid
Restrictions / Comments:

Important
Ensure that the patient is maintained on a specific manufacturer’s product
Unlicensed phenobarbital liquid 50mg/5ml (sugar and alcohol free) for paediatric use (as recommended by the RCPCH and NPPG).
 
Links :
CD
Off Label
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Restrictions / Comments:

Important

Ensure that the patient is maintained on a specific manufacturer’s product. Phenytoin sodium is NOT EQUIVALENT to Phenytoin base (suspension). When switching between products, 100mg of phenytoin sodium is approximately equivalent to 92mg of phenytoin base.

https://www.gov.uk/drug-safety-update/phenytoin-risk-of-stevens-johnson-syndrome-associated-with-hla-b-1502-allele-in-patients-of-thai-or-han-chinese-ethnic-origin

https://www.gov.uk/drug-safety-update/antiepileptics-adverse-effects-on-bone

https://www.gov.uk/drug-safety-update/antiepileptic-drugs-in-pregnancy-updated-advice-following-comprehensive-safety-review

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Tablets
Restrictions / Comments:

Important
Prescribe by brand - ensure patient is maintained on a specific product.
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules (slow release)
  • Crushable tablets
  • Gastro-resistant tablets
  • Granules (slow release)
  • Modified release tablets
  • Oral solution
  • Tablets
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Restrictions / Comments:

Important
Capsules (Sprinkle) reserved for use in patients who cannot swallow tablets. Liquid reserved for patients who cannot swallow tablets or capsules
 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Sachets (powder)
  • Tablets
Restrictions / Comments:

Important
Specialist initiation before transfer of prescribing to primary care
 
Links :
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Soluble tablets
Restrictions / Comments:

 
Links :
NFD1
SPC
Indication :
Status :
Blue
Formulations :
  • Capsules
Restrictions / Comments:

 
Links :
SPC
Indication :
Status :
Blue
Formulations :
  • Oral suspension
Restrictions / Comments:

Important
Zonisamide 20mg/ml is the only licensed oral suspension available.
 
Links :
SPC
Indication :
Status :
Amber
Formulations :
  • Tablets
Restrictions / Comments:

Important
SASH - restricted to paediatrics only. RSCH - only initiate on recommendation from a tertiary referral centre.
 
Links :
R
SPC
Indication :
Status :
Amber
Formulations :
  • Oral suspension
Restrictions / Comments:

Important

RSCH - only initiate on recommendation from a tertiary referral centre.

 
Links :
R
SPC
Indication :
Status :
Amber
Formulations :
  • Capsules (slow release)
  • Crushable tablets
  • Gastro-resistant tablets
  • Granules (slow release)
  • Modified release tablets
  • Oral solution
  • Tablets
Restrictions / Comments:

Important

Pregnancy Prevention Programme required. See MHRA advice

Principles for shared care found here: https://surrey.res.services/PAD/Profile/NonClinicalProfile/9136

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Injection
Restrictions / Comments:

Important

Pregnancy Prevention Programme required. See MHRA advice

 
Links :
SPC
Indication :
Status :
Red
Formulations :
  • Oral solution
Restrictions / Comments:

Important
Specialist centres only (including ongoing supply)
 
Links :
CD
SPC
Indication :
Status :
Red
Formulations :
  • Capsules
Restrictions / Comments:

Important

For initiation and dose adjustments by specialists in Epilepsy only.

 
Links :
SPC
Indication :
Status :
Non Formulary
Formulations :
  • Oral suspension
Restrictions / Comments:

 
Links :
NFD2
SPC
Indication :
Status :
Non Formulary
Restrictions / Comments:

 
Links :
NFD1
SPC